Late March of 2019, a collection of European technology investors made waves in the psychedelic medicine industry, amassing the largest-ever private financing round for biotech company, ATAI Life Sciences (“ATAI”). According to ATAI’s press release, the German-based company’s Series B financing … Read more about Psychedelic Medicine’s Rise in 2019
MAPS Announces Progress in Two PTSD Studies
In the organization’s monthly newsletter, the Multidisciplinary Association for Psychedelic Studies (“MAPS”) announced two milestones in separately conducted clinical trials, both dedicated to the treatment of post-traumatic stress disorder (“PTSD”). This month, MAPS received approval for the … Read more about MAPS Announces Progress in Two PTSD Studies
Iowa Bill to Legalize Psilocybin Mushrooms and MDMA
In a surprising move late last week, Iowa Rep. Jeff Shipley (R) filed two pieces of legislation in the Iowa state legislature to legalize specific psychedelic substances as treatments. The first bill would approve the medical use of psilocybin, methylenedioxymethamphetamine (“MDMA”), and ibogaine – … Read more about Iowa Bill to Legalize Psilocybin Mushrooms and MDMA
MDMA-Assisted Psychotherapy Study Expands Screening
Multidisciplinary Association for Psychedelic Studies (“MAPS”), a non-profit research, advocacy, and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and empathogens, has recently announced the expansion of their … Read more about MDMA-Assisted Psychotherapy Study Expands Screening